SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of NAV, UROV, AKER, and EMIS Mergers
01 déc. 2020 11h09 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Navistar International Corporation (NYSE: NAV) regarding possible breaches of...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of HDS, UROV, AKER, and TGC Mergers
19 nov. 2020 18h11 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: HD Supply Holdings, Inc. (NASDAQ GS: HDS) regarding possible breaches of...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Akers Biosciences, Inc. Merger
13 nov. 2020 11h31 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Akers Biosciences, Inc. (“Akers”) (NASDAQ GS: AKER) regarding possible breaches of...
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
11 août 2020 08h00 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several...
Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
14 mai 2020 13h00 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
14 mai 2020 09h33 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas...
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
07 avr. 2020 10h53 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
24 mars 2020 09h00 HE
|
Akers Biosciences Inc.
Established D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for CoronavirusCurrent Regulatory environment could lead to...
Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation
17 janv. 2020 17h00 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached...
Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering
09 déc. 2019 11h40 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...